KMT2C and KMT2D aberrations in breast cancer
KMT2C and KMT2D are histone lysine methyltransferases responsible for the monomethylation of histone 3 lysine 4 (H3K4) residues at gene enhancer sites. KMT2C/D are the most frequently mutated histone methyltransferases (HMTs) in breast cancer, occurring at frequencies of 10-20% collectively. Frequent damaging and truncating somatic mutations indicate a tumour-suppressive role of KMT2C/D in breast oncogenesis. Recent studies using cell lines and mouse models to replicate KMT2C/D loss show that these genes contribute to oestrogen receptor (ER)-driven transcription in ER+ breast cancers through the priming of gene enhancer regions. This review provides an overview of the functions of KMT2C/D and outlines the recent clinical and experimental evidence of the roles of KMT2C and KMT2D in breast cancer development.
Funding
North-East Cancer Research and Education Trust (NECRET)
RCSI StaR MD Programme
Science Foundation Ireland (SFI) (21/FFP-P/10191)
History
Comments
The original article is available at https://www.sciencedirect.com/Published Citation
Tinsley E, Bredin P, Toomey S, Hennessy BT, Furney SJ. KMT2C and KMT2D aberrations in breast cancer. Trends Cancer. 2024:S2405-8033(24)00029-3.Publication Date
7 March 2024External DOI
PubMed ID
38453563Department/Unit
- Physiology and Medical Physics
- Molecular Medicine
- Beaumont Hospital
Publisher
Elsevier B.V.Version
- Accepted Version (Postprint)